We use cookies to provide you with a better experience. If you continue to use this site, we'll assume you're happy with this. Alternatively, click here to find out how to manage these cookies

hide cookie message
RSS FeedPeople Management

AstraZeneca plans 7,300 global job losses


FTSE 100 drugmaker facing losses from expired patents

Article comments

FTSE 100 drug company AstraZeneca is to cut a further 7,300 jobs worldwide, on top of the 9,000 job losses since 2010, it announced on Thursday.

The Anglo-Swedish company aims to save £1 billion annually by the end of 2014, at an upfront cost of around £1.3 billion. It is unclear where the jobs will be lost in its 61,000 worldwide headcount, which includes 8,000 in the UK.

The drugmaker is facing losses as many of its best-selling drugs, such as antipsychotic medicine Seroquel and heartburn treatment Nexium, lose their patents in the next few years.

Chief executive David Brennan said: "The further expected losses of market exclusivity make for a challenging 2012 outlook."

There has been speculation that the company will have to make a large acquisition to make up for the lack of big drugs in the pipeline. Following the poorly received purchase of MedImmune in 2007, the company has so far eschewed another large deal. But that strategy could be up for review, especially with the group casting around for an outsider to replace current chairman Louis Schweitzer.

Doubts about AstraZeneca's future have grown since a double blow to its new drug pipeline in December when it scrapped an ovarian cancer drug and took a big writedown on an experimental antidepressant.

Its existing cardiovascular business is also uncertain, with new drug Brilinta off to a slow start and cholesterol fighter Crestor facing more competition following the arrival of cheap generic copies of Pfizer's market-leading Lipitor.

AstraZeneca now expects recently launched products and the pipeline to contribute $2-4 billion to sales by 2014, down from $3-5 billion estimated a year ago.

Despite the challenges, AstraZeneca is committed to returning cash to shareholders and the company announced it planned to buy back $4.5 billion in shares in 2012.

Drug stocks have outperformed the broader market in recent months, with investors attracted by their healthy dividend yields, but growth is elusive for many of the big firms.

Pfizer, the world's biggest drugmaker, reported a sharp fall in quarterly earnings two days ago and trimmed its 2012 forecasts, while European rival Novartis also said it expected lower profitability this year.

Share:

Recommended Articles

Comments

AstraZeneca plans 7,300 global job losses
People Management

Is the CFO still the sole sacrificial lamb when a company struggles?

Is the CFO still the sole sacrificial lamb when a company struggles?

Tesco's announcement today that boss Philip Clarke is to leave proves that's no longer the casemore ..


Diageo brings Facebook’s Nicola Mendelsohn on board

Mendelsohn is an expert in digital marketingmore ..

Engineer Babcock International promotes group FD

Its financial controller of 12 years will step up to be the new group FD as Bill Tame becomes CEO of the international divisionmore ..

Tesco ex-FD appointed Morrison’s next chairman

Andrew Higginson served as finance director at Tesco for 15 yearsmore ..

Ten tactics to unleash the potential of Generation Y in finance

Most CFOs are Baby Boomers or Generation X-ers – the difference in mindset is hugemore ..

What's the role of the finance chief in a takeover bid?

With Pfizer's possible takeover of Astrazeneca in the spotlight we take a look at how pivotal the CFO is in such a dealmore ..

Send to a friend

Email this article to a friend or colleague:


PLEASE NOTE: Your name is used only to let the recipient know who sent the story, and in case of transmission error. Both your name and the recipient's name and address will not be used for any other purpose.



In Depth
Can finance rise to the challenge of major transformation?

Can finance rise to the challenge of major transformation?

Outdated finance processes, systems and competencies leave too many questions unanswered more ..

In Depth
Interim CFO or consultant? The pros and cons

Interim CFO or consultant? The pros and cons

Ed Harding offers an insight into the life of an interim CFO and the advantages in driving transformation more ..

Advertisement

* *